Navigation Links
Fibrocell Science, Inc. Announces Addition of Dr. George J. Korkos to Board of Directors
Date:7/20/2010

EXTON, Pa., July 20 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that George J. Korkos, M.D., D.D.S., F.A.C.S., has been appointed to its board of directors.

Dr. Korkos currently serves as President of both Plastic Surgery Associates and Rejuva Skin Care & Laser Center (leaders in use of Botox® and fillers), each of which is located in Waukesha, Wisconsin. He also presently serves as Associate Clinical Professor at the Medical College of Wisconsin in Milwaukee.

"As a plastic surgeon and dentist with vast experience as a clinician as well as previous roles as scientific advisor to healthcare-focused companies, George will add valuable perspective to our board of directors as we begin to evaluate applications for our lead therapy in periodontics and reconstructive dentistry," said Chairman and CEO David Pernock.

Dr. Korkos was board certified in plastic surgery in 1967 and recertified in 1978. He is or has been a member of numerous prestigious medical societies, is an experienced academic lecturer and author and has presented on a variety of plastic and reconstructive surgery topics at meetings of regional and national medical associations. He has previously served as scientific advisory board member to Cellgen Company, Sleep Holding Company and Skin Visible Company. He also is Co-founder and former Contact Director and Investor of the Milwaukee Bucks Expansion Basketball Team.

Dr. Korkos pursued undergraduate studies at Marquette University, received his D.D.S. from Marquette University School of Dentistry, his M.D. and general surgery degrees from Medical College of Wisconsin, and his degree in plastic and reconstructive surgery from St. Louis University Medical School. He completed his residencies and held fellowships at Medical College of Wisconsin and St. Louis University Group of Hospitals.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.  For additional information, please visit www.fibrocellscience.com.

Forward-Looking Statements  

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.


'/>"/>
SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.s Declan Daly as Irish Life Science 50 Member
2. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
3. Fibrocell Science, Inc. Enters Into Financing Agreement
4. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
5. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
8. ‘Next Big Idea' Fest Aims to Spark Interest Among NM Youth in Science, Technology as Future Career Path
9. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
10. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
11. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):